European Pharmaceutical Review

DECEMBER 20, 2023

In October 2023, the European Parliament (EP) proposed revisions to the European Commission proposals with diverging views on various topics set out through two documents. cited 2023Dec] Available from: [link] pdf The post EU pharmaceutical legislation revisions: what are the implications for biopharma?

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

Pharmaceutical Technology

OCTOBER 5, 2022

As per the US Department of Justice, Biogen paid remuneration in the form of training and consulting fees and speaker honoraria, to induce physicians to prescribe the company’s drugs, in violation of the Anti-Kickback Statute.

Government 59

Government Specialization Physicians Marketing 59

European Pharmaceutical Review

FEBRUARY 7, 2023

Following publication of the proposal, the European Commission launched an eight-week public consultation. The stakeholder consultation resulted in 246 comments and ended on 18 January 2023. However, the eight-week period was quickly shortened to eight days.

Medical 117

Medical Government Marketing Medicine 117

PM360

APRIL 7, 2023

Introducing CiTRUS Health Group CiTRUS Health Group has launched as a robust, boutique strategic consulting business that allows clients to clearly articulate the scientific, clinical, and real-world evidence to establish a strong value proposition and ultimately successful commercialization.

Healthcare 52

Healthcare Healthcare Marketing Government 52

European Pharmaceutical Review

JUNE 24, 2022

He is now an independent GMC consultant. Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products, 24 March 2022 EMA/409815/2020 Rev.8. About the author. Nitrosamine Imp -Q&A-Mar-22.pdf.

Food and Drug Administration 52

Food and Drug Administration Manufacturing Food FDA 52

PM360

SEPTEMBER 28, 2022

This was back in 2004/2005 when we were just hearing about biosimilars for the first time and they were the great unknowns. I hear many times whether it’s from consultants, vendors, customers, or other colleagues, how some of them profess to be experts in the biosimilar space. I don’t believe that for a minute.

Competition 98

Competition Marketing Manufacturing Biopharma 98

Evolve Your Success

JUNE 20, 2023

They do their things as well like consulting and conferences. I started podcasting in 2004 to cover the Celtics when everybody else in New England was talking about the Patriots and the Red Sox. Lindsay Brown for one brand and Melanie creates all the content for the other. He is my co-host for the other podcast.

Medical sales 130

Medical sales Sales Medical Healthcare 130

European Pharmaceutical Review

FEBRUARY 28, 2023

He is currently a CMC consultant with an interest in impurities and safety‑based limits. Questions and Answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. Available from: [link] 10.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical FDA Medicine 98

European Pharmaceutical Review

JULY 4, 2024

4,6 Traditional Herbal Registration The Traditional Herbal Medicines Directive (Directive 2004/24/EC) is implemented in the UK by the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 and came into force on 30 April 2011. Premier Consulting [Internet]. 2012/1916). 2018 [cited 2024May]. Ethnopharmacol.

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

European Pharmaceutical Review

JUNE 8, 2023

He is currently a CMC consultant with an interest in impurities and safety‑based limits. Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP).

Food and Drug Administration 59

Food and Drug Administration FDA Manufacturing Law & Regulation 59

European Pharmaceutical Review

JULY 20, 2023

Next steps The public consultation period ended on 8 September 2022 and feedback provided is currently being assessed by the European legislator. States will also retain full competences on ethical decisions regarding the provision of SoHO-based treatments in their respective healthcare systems. Cited 2023Mar].

Safety 75

Safety Distribution Food Medical 75

World of DTC Marketing

MAY 2, 2022

The top executive at McKinsey & Company appeared before Congress to answer for the consulting firm’s role in fanning the opioid crisis and came under intense criticism from lawmakers. Yet, pharma continues to be aligned with MBA spreadsheet consulting. rules requiring tougher language for painkiller labels.

Consulting 234

Consulting Doctors Pharma Sales 234

Cadensee

JULY 20, 2021

When he was going through his cancer, he died in 2004. I need to consult.' Uri Goren: So, I guess my fascination with this came through a personal experience. So, I myself, was a care giver for my father. And I've learned the power of digital or internet through that experience. This and this are a problem, I still don't know.

Food and Drug Administration 52

Food and Drug Administration Doctors Healthcare Healthcare 52

European Pharmaceutical Review

AUGUST 22, 2022

He is now an independent GMC consultant. Procedure under Article 5(3) of Regulation EC (No) 726/2004. The authors indicated that the AIs of several of these API nitrosamine groups were found to be much higher than the corresponding simple nitrosamines, which results in a commensurately higher analytical LoQ. About the author.

Food and Drug Administration 59

Food and Drug Administration Prescription Food Medicine 59

European Pharmaceutical Review

DECEMBER 23, 2024

He is now an independent GMC consultant. EMA/CHMP/ICH/167068/2004. PCQS16,17 approaches support accelerated development and manufacturing flexibility, as the impact of process changes on quality would be assessed in an objective fashion and would not necessarily require changes to the productspecification. Pharmaceutics. 22 June 2017.

Safety 52

Safety Pharmaceutical Manufacturing Management 52